source
- FDA Announces First Participant Selected for TEMPO for Digital Health Devices PilotThe U.S. Food and Drug Administration today announced the first manufacturer selected for the Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot.fda press · 8d ago↗ source
- Dimerix buys a kidney injury drug; Arpeggio appears to be winding downPlus, news about Takeda, Novartis and Regenxbio. 🤝 Mission sells kidney injury drug to Dimerix: Dimerix will pay $5 million upfront for Mission’s Phase 2-ready candidate for acute kidney injury, k…Endpoints · 13d ago↗ source
- Nava Therapeutics emerges with $89M for lipid nanoparticlesNava Therapeutics, a secretive startup that’s been working on a new generation of lipid nanoparticles that target the bone marrow, immune cells and the kidney, has raised $89 million, the company t…